

Merlin Biomed Limited

Financial Statements for the year ended 31 March 2008

Registered number: 3504725

FRIDAY



AXLYM5S9

A59

19/12/2008

344

COMPANIES HOUSE

Merlin Biomed Limited

Registered No. 3504725

Directors Mr M. J. Docherty

Secretary Ms S. L. Dichlian (Appointed, 14 April 2008)
Mr M. J. Hoy (Resigned, 14 April 2008)

Registered Office 33 King Street
St James's
London
SW1Y 6RJ

Merlin Biomed Limited

Balance Sheet as at 31 March 2008

| | Notes | 2008 £ | 2007 £ |
|--------------------------|-------|------------|------------|
| Cash at bank and in hand | | <u>500</u> | <u>500</u> |
| Called-up share capital | 2 | <u>500</u> | <u>500</u> |

The Company was dormant throughout the period of these financial statements

The notes on page 3 form an integral part of these financial statements

For the year ended 31 March 2008 the company was entitled to exemption under section 249aa(1) of the Companies Act 1985.

No members have required the company to obtain an audit of its accounts for the year in question in accordance with section 249b(2).

The director's acknowledge their responsibility for: (i) Ensuring the company keeps accounting records which comply with section 221; and (ii) preparing accounts which give a true and fair view of the state of affairs of the company as at the end of its financial year, and of its profit or loss for the financial year in accordance with section 226, and which otherwise comply with the requirements for the Companies Act relating to accounts, so far as applicable to the company.

The financial statements on pages 2 to 3 were approved by the board of directors on 27 November 2008 and were signed on its behalf by;

..... Director
..... Director/Secretary

Merlin Biomed Limited

Notes to financial statements For the year ended 31 March 2008

1 Accounting policies

A summary of the principal accounting policies, all of which have been applied consistently throughout the year, is set out below.

a) Basis of accounting

The financial statements are prepared under the historical cost convention and in accordance with applicable accounting standards in the United Kingdom.

Under Financial Reporting Standard 1 the Company is exempt from the requirement to prepare a cash flow statement on the grounds that its ultimate parent undertaking includes the Company in its own consolidated financial statements.

As the Company is a wholly owned subsidiary of Merlin Biosciences Limited, the Company has taken advantage of the exemption contained in FRS 8 and has therefore not disclosed transactions or balances with entities which form part of the group.

2 Called-up share capital

| | 2008 £ | 2007 £ |
|---|--------------|--------------|
| <i>Authorised</i> | | |
| 1,000,000 ordinary shares of 0.1p each | <u>1,000</u> | <u>1,000</u> |
| <i>Allotted, called-up and fully paid</i> | | |
| 500,100 ordinary shares of 0.1p each | <u>500</u> | <u>500</u> |

3 Ultimate holding company

The immediate parent undertaking is Merlin Biosciences Limited. The Company's ultimate holding company is Bricktown Limited, a company registered in England.